📢 In HFmr/pEF patients, combination therapy with SGLT2 inhibitors and MRAs leads to a greater reduction in NT-proBNP compared to either agent alone✅
However, it is associated with a more pronounced decline in eGFR❗️
Balancing benefits and risks is key!
#HeartFailure2025
It was a great pleasure to present in front of leading experts and colleagues from around the world!
So much to learn from their expertise, grateful for the opporturnity!
#HeartFailure2025